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Objectives.Thesigniﬁcanceofsplenectomyinadvancedproximalgastriccancerisexaminedretrospectively.Methods. From1994to
2004, 505 patients with advanced proximal gastric cancer underwent curative total gastrectomy with preserving spleen (T) for 264
patients and total gastrectomy with splenectomy (ST) for 241 patients. Results. Patients who underwent splenectomy showed more
advanced lesions. The metastatic rate of lymph node (LN) in the splenic hilus (No. 10) in ST was 18.3%. As for the incidence of
surgical complications, there was not statistically diﬀerence except for pancreatic ﬁstula. The index of estimated beneﬁt of (No. 10)
LN was 4.2, which was similar to that of (No. 9), (No. 11p), (No. 11d), and (No. 16) LNs. 5-year survival rate of (No. 10) positive
group was 22.2%. 5-year survival rates of pSE and pN2 in T group were better than that of pSE and pN2 in ST, respectively. The
superiority of ST was not conﬁrmed even in Stage II, IIIA, and IIIB. Conclusion. Splenectomy was not eﬀective for patients with
(No.10)metastasisinlong-termsurvival. Spleen-preservingtotalgastrectomywill befeasibleandbeenoughtoaccomplish radical
surgery for locally advanced proximal gastric cancer.
1.Introduction
Although it is well known that lymph node (LN) metastasis
is an important factor in the prognosis of gastric cancer,
the optical extent of LN dissection remains controversial.
Splenectomy has been indicated to remove the LNs sur-
rounding the splenic artery (No. 11) and splenic hilum
(No. 10). Previous reports suggested that gastrectomy with
splenectomy resulted in better survival than gastrectomy
alone in gastric cancer patients [1]. The Japanese retrospec-
tive studies revealed that the frequency of LN metastasis to
No. 10 in proximal gastric cancer was 15–20%, and the 5-
year survival rate was 20–25% [2, 3]. Total gastrectomy with
splenectomy is considered to be a standard procedure for
proximal advanced gastric cancer in gastric cancer treatment
guidelines[4].Buttwolargeprospectiverandomizedtrialsin
westerncountriesreportedthatsplenectomywasariskfactor
for morbidity and mortality [5, 6]. Preservation of the spleen
during extended lymphadenectomy decreases complications
with no clear evidence of improvement or detriment to
overall survival [7]. Then modiﬁed D2 lymphadenectomy
avoiding splenectomy is now accepted as a standard pro-
cedure in the west countries. Our retrospective study was
designed to investigate the signiﬁcance of splenectomy by
evaluating postoperative morbidity, frequency of the each
LN metastasis, and long-term surgical outcomes of locally
advanced proximal gastric cancer patients who underwent
total gastrectomy with R0 resection.
2. Patients andMethods
2.1. Pathological Examination of Lymph Nodes. All regional
LNs were separated immediately after gastrectomy by the
operators. Node numbers were recorded using a LN map
(Figure 1). Nodes were assigned to the appropriate anatom-
ical stations according to Japanese Classiﬁcation of Gastric
Carcinoma (JCGC) of the 2nd English edition [8]. Nodes
found at each station were labeled and immediately sent for
histological examination.2 International Journal of Surgical Oncology
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and numbered. Regional lymph node stations are deﬁned as No. 1, right paracardial LN; No. 2, left paracardial; No. 3, LN along the
lesser curvature; No. 4sa, LN along the short gastric vessels; No. 4sb, LN along the left gastroepiploic vessels; No. 4d, LN along the right
gastroepiploic vessels; No. 5, suprapyloric LN; No. 6, infrapyloric LN; No. 7, LN along the left gastric artery; No. 8a LN along the common
hepatic artery; No. 9, LN around the celiac artery; No. 10 LN at the splenic hilum; No. 11p, LN along the proximal splenic artery; No. 11d,
LN along the distal splenic artery; No. 12a, LN in the hepatoduodenal ligament; No. 13, LN on the posterior surface of the pancreatic head;
No. 14v, LN along the superior mesenteric vein; No. 16, LN around the abdominal aorta. APIS, left inferior phrenic artery; GB, short gastric
artery; AGES, left gastroepiploic artery; VCM, middle colic vein; VGED, right gastroepiploic vein; VCDA, accessory right colic vein; VCD,
right colic vein; AGP, posterior gastric artery; VL, splenic vein; AJ, jejunal artery; VJ, jejunal vein; ACM, middle colic artery; ACD, right colic
artery; TGC, gastrocolic trunk; VMS, superior mesenteric vein; VPDIA, anterior inferior pancreaticoduodenal vein; AHC, common hepatic
artery; VP, portal vein.
2.2. Patient Population. From 1994 to 2004, 505 patients
with a single gastric adenocarcinoma located in the upper
third portion underwent curative total gastrectomy at
Niigata Cancer Center Hospital. Among them, 240 patients
underwenttotalgastrectomywithsplenectomy(ST),because
the tumor involved the greater curvature or enlarged LN of
No.10and/orNo.11.Theremaining265patientsunderwent
spleen-preserving lymphadenectomy (T) and remove No.International Journal of Surgical Oncology 3
Table 1: Clinicopathological characteristics of the patients who
underwent total gastrectomy with or without splenectomy (N =
505).
Characteristics T
N = 265 (%)
ST
N = 240 (%)
P value
Age (year) 0.121
<70 163 (61.5) 18 (75.0)
≥70 102 (39.5) 60 (25.0)
Age (year) 0.481
Male 198 (74.7) 172 (71.7)
Female 67 (25.3) 68 (28.3)
Gross type <0.001
Type 0, 1, 2 221 (83.4) 100 (41.7)
Type 3, 4 44 (16.6) 140 (58.3)
Tumor location <0.001
U 191 (72.1) 159 (66.3)
M, L 60 (22.6) 34 (14.2)
UML 14 (5.3) 47 (19.6)
Histological type <0.001
Diﬀerentiated 151 (57.0) 97 (40.4)
Undiﬀerentiated 114 (43.0) 143 (59.6)
Depth of invasion <0.001
pT1, T2 228 (86.0) 78 (32.5)
pT3, T4 37 (14.0) 162 (67.5)
Lymph node metastasis <0.001
pN0, N1 220 (83.0) 123 (51.3)
pN2, N3 45 (17.0) (48.8)
∗U; upper third, M; middle third, L; lower third.
11 but not No. 10. The clinicopathological features, stage
and 5-year survival rates according to JCGC were compared
between ST group and T group.
2.3. Procedures. Total gastrectomy with D2 and more exten-
sive lymphadenectomy was performed according to the rules
of the JCGC. The standard reconstruction was Roux-en Y
method. In T group, No. 11 was dissected along the upper
border of the pancreas but not No. 10 with or without
mobilization of the spleen from the retroperitoneum. When
the tumor involved the greater curvature and/or enlarged
LN suspected metastasis at splenic hilum was found before
or during operation, splenectomy was performed simul-
taneously as R0 resection. The index of estimated beneﬁt
from lymphadenectomy was calculated by multiplying the
incidence of each nodal station by the 5-yer survival rate of
patients with metastasis to that nodal station [9].
2.4. Statistical Analysis. All statistical analyses were con-
ducted using the statistical program SPSS version 19 for
Windows (SPSS, Chicago, IL, USA). Clinicopathological
variables were analyzed using the chi-square test and the
Student’s t-test. The risk factors for No. 10 metastasis were
determined using logistic regression analysis. Cumulative
survival rates were calculated by the Kaplan-Meier method,
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Figure 2: Incidence of each lymph node metastasis in ST group.
The metastatic rate of the splenic hilar LN (No. 10) was 18.3%.
and the signiﬁcance of the diﬀerences in survival was deter-
mined by the log-rank test. P-value of <0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Comparison of the Clinicopathological Features. Clinico-
pathological features are shown in Table 1. There was no
statistical diﬀerence in age and gender between ST group and
T group. But there were signiﬁcant diﬀerences between two
groupsregardinggrosstype,tumorlocation,andhistological
type, depth of the tumor invasion, and status of lymph node
metastasis. Namely, type 3 and type 4, UML (U; the upper,
M; the middle, L; the lower), undiﬀerentiated type, pT3
and pT4, and pN2 and pN3, are found frequently in ST
group. Patients who underwent splenectomy showed more
advanced lesions.
3.2. Perioperative Morbidity. Postoperative complications
were listed in Table 2. There was no signiﬁcant diﬀerence
between two groups concerning nonsurgical complications.
The incidence of surgical complications regarding anasto-
motic leakage, pancreatic ﬁstula, postoperative ileus, and
intra-abdominal bleeding was higher in ST group than in
T group. But there was no statistical diﬀerence except for
pancreatic ﬁstula (P = 0.008).
3.3. Lymph Node Metastasis in ST Group. The lymph node
metastatic rate in ST group was shown in Figure 2.N o .3
metastatic rate was highest (58.8%). The incidence of No. 10
metastasis was 18.3%, which was similar to that of No. 4sb
(20.5%), No. 6 (19%), No. 9 (19.5%), and No. 11p (20.2%).
No. 16 metastatic rate was 36.3% which was unexpectedly
high.
The 5-year survival rate was 22.2% in patients with No.
10 metastasis and 50.8% in patients without its metastasis in
ST group (Figure 3).
3.4. The Therapeutic Value of Lymph Node Dissection. The
therapeutic value of extended lymph node dissection was
estimated by multiplication of incidence of lymph node4 International Journal of Surgical Oncology
Table 2: Perioperative morbidity following total gastrectomy with or without splenectomy.
Complication T
(without splenectomy)
ST
(with splenectomy)
P value
Nonsurgical complication
Cardiovascular 3 (1.1) 2 (0.8) N.S.
Pulmonary 7 (2.6) 8 (3.3) N.S.
Liver dysfunction 02 ( 0 . 8 ) N.S.
Renal dysfunction 02 ( 0 . 8 ) N.S.
CNS disorder 2 (0.8) 2 (0.8) N.S.
Others 6 (2.3) 7 (2.9) N.S.
Surgical complication
Anastomotic leakage 1 (0.4) 4 (1.6) N.S.
Panctreatic ﬁstula 16 (6.0) 31 (12.9) 0.008∗
Postoperative 22 (8.3) 21 (8.7) N.S.
Bleeding 03 ( 1 . 3 ) N.S.
N.S., not signiﬁcant. ∗signiﬁcant diﬀerence.
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Figure 3: Comparison of cumulative survival curves of ST group
between with or without No. 10 metastasis. The prognosis of the
patients with No. 10 positive was poorer than that of the patients
with No. 10 negative (P<0.001).
metastasisand5-yearsurvivalrateofpatientswithmetastasis
for each station. The index of estimated beneﬁt of No. 10 was
4.2, which was similar to that of No. 9 (4.8), No. 11p (3.8),
No. 11d (3.9), and No. 16 (3.7) (Figure 4). Almost all the
regional lymph nodes of upper third portion of the stomach
hadhigheﬀectindexoflymphadenectomy,butthetreatment
index of No. 4a and No. 8a was lower than that of No. 10.
3.5. Survival. In the survival rate according to depth of
tumor invasion, ST group revealed lower prognosis com-
pared with T group, but there was no signiﬁcant diﬀerence
between two groups in T2a and T2b (Figure 5(a)).
But the survival rate for patients with pSE (T3: tumor
penetration of serosa), there was signiﬁcantly diﬀerence
between ST group (48.1%) and T group (67.7%). In the
survival rate according to lymph node metastasis, there was
no signiﬁcant diﬀerence in the cumulative survival rates
between two groups in pN0 and pN1 (Figure 5(b)).
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Figure 4: Eﬀect index of estimated beneﬁt from lymphadenectomy
in ST group. The index was calculated by multiplication of the
frequency of metastasis to the station and the 5-year survival rate
of patients with metastasis to that station. The index of estimated
beneﬁt of No. 10 was approximately equal to that of No. 9, No. 11p,
No. 11d, and No. 16.
But in the survival rate for patients with pN2, there was
signiﬁcantly diﬀerence between ST group (46.1%) and T
group(66.7%).Asforthesurvivalrateaccordingtostage,the
survival of ST group was lower than that of T group in stages
II, IIIA, and IIIB, but there was no signiﬁcant diﬀerence
(Figure 5(c)).
4. Discussion
The current standard treatment for proximal advanced
gastric cancer in Japan is total gastrectomy with D2 lym-
phadenectomy. In order to accomplish D2 lymphadenec-
tomy, splenectomy had been justiﬁed for complete removal
of No. 10 as extended radical surgery. But extended resection
which is regarded as a standard procedure in Asian countries
isnoteﬀectiveinWesterncountries.ThesplenectomycausedInternational Journal of Surgical Oncology 5
Survival curves according to the depth of invasion
5 
(years)
(
%
)
0
100
N.S
T (N = 49 ) 84.2%
ST (N = 19 ) 77.3%
pMP
5 
(years)
N.S
(
%
)
0
100 T (N = 38 ) 71.5%
ST (N = 59 ) 61.9%
pSS
5 
(years)
(
%
)
0
100
pSE
T (N = 34 ) 67.7%
P = 0.007
ST (N = 126 ) 48.1%
(a)
Survival curves according to the lymph node metastasis
5 
(years)
(
%
)
0
100
pN1
N.S
T (N = 60 ) 67.1%
ST (N= 60 ) 56.3%
5 
(years)
(
%
)
0
100
pN0
N.S
ST (N = 63 ) 83.7%
T (N = 178 ) 77.1%
5 
(years)
(
%
)
0
100
pN2
T (N = 25 ) 66.7%
P = 0.031
ST (N = 77 ) 46.1%
(b)
Survival curves according to stages
(
%
)
0
100
Stage II
5 
(years)
N.S
T (N = 45 ) 73.3%
ST (N = 33 ) 62.6%
(
%
)
0
100
Stage IIIA
5 
(years)
N.S
T (N = 26 ) 69.7%
ST (N = 52 ) 53.1%
(
%
)
0
100
Stage IIIB
5 
(years)
N.S (P = 0.073 )
T (N = 11 ) 72.7%
ST (N = 60) 41.2%
(c)
Figure 5: (a) Cumulative survival rates according to the depth of invasion (pT). As for pMP and pSS, there was no diﬀerence between T
groupandSTgroup,butthesurvivaloftheTgroupwithpSEwasbetterthanthatofSTgroupwithpSE(P = 0.007).(b)Cumulativesurvival
rates according to lymph node metastasis (pN). There was no diﬀerence in the cumulative survival rates between two groups with pN0 and
pN1, but the survival of T group with pN2 was better than that of ST group with pN2 (P = 0.031). (c) Cumulative survival curves according
to stage (pStage). There was no signiﬁcant diﬀerence in the cumulative survival rates between two groups with Stage II, Stage IIIA, and Stage
IIIB.
high morbidity and mortality, and it was shown to be an
independent prognostic risk factor on multivariate analysis
in node-negative patients in previous studies [10–15]. On
the other hand, the splenectomy is considered to be a
safe procedure that does not decrease surgical mortality
[16]. A Korean trial has also reported that postoperative
morbidity after splenectomy for D2 lymphadenectomy was
not higher than simple total gastrectomy, but there was no
signiﬁcant diﬀerence in 5-year survival between with and
without splenectomy [17]. Patients with proximal advanced
gastric cancer localized on the greater curvature and type 4
might obtain relatively high survival beneﬁts from No. 106 International Journal of Surgical Oncology
lymphadenectomy [18] .T h es p l e n e c t o m yh a sb e c o m eas a f e
technical procedure, but the surgical procedure of a total
gastrectomywithsplenectomyshouldbeperformedatahigh
volume hospital to avoid the postoperative complications.
The frequency of No. 10 metastasis was reported to be
high in proximal advanced gastric cancer located on the
greater curvature or in the posterior wall of the stomach,
and lymphatic pathways along the posterior gastric artery,
splenic artery, short gastric vessels, and/or gastroepiploic
vessels were suggested to be important for No. 10 metastasis
[19]. Lymphography has demonstrated that the lymphatic
ﬂow from the left upper region of the stomach enters the
lymph node in the splenic hilum and travels to the nodes
around the celiac trunk along the splenic artery [20]. In our
study, the location involving the greater curvature, pN3 and
No. 11d metastasis were risk factors for No. 10 metastasis,
and the frequency of No. 10 metastasis was similar to that
of No. 4sb, No. 9, and No. 11p metastasis. Furthermore,
LN dissection eﬀect index of No. 10 was almost as same
as that of No. 9, No. 11p, and No. 11d. But the prognosis
of patients with No. 10 metastasis was still poor even after
its dissection. Furthermore, splenectomy does not improve
survival of patients with proximal advanced gastric cancer
even though curative resection was performed [21, 22].
Multivariate analysis demonstrated that nodal metastasis
was independent prognostic factor, but splenectomy was
not [23]. These reports suggested that the patients with
No. 10 metastasis had already too extended LN metastasis
to improve the prognosis. Accordingly, the splenectomy
for D2 lymphadenectomy may be unnecessary in all the
patients with advanced gastric cancer. On the contrary, some
authors have found the survival beneﬁt and recommended
splenectomy for No. 10 lymphadenectomy. The splenectomy
was one of the independent prognostic factors, and total
gastrectomy with splenectomy is recommended for patients
with No. 10 positive T3 proximal gastric cancer [24]. The
survival of No. 10 positive patients was not to be diﬀerent
from that of No. 10 negative patients when curative surgery
was performed [25]. The splenectomy was recommended
when the tumor was located on the greater curvature or
posterior wall of the stomach and had No. 4sa, No. 4sb, or
No. 11 metastasis [19]. In fact, it is diﬃcult to detect the
depthoftumorinvasionandNo.10and/orNo.11metastasis
though a preoperative and intraoperative diagnostic tech-
nique. In Germany, No. 10 metastasis was observed only
in advanced cancer, particularly in tumors located in the
greater curvature and/or type 4 tumors [26]. Our current
study showed that splenectomy adversely aﬀected survival
in pSE and pN2, while there was no signiﬁcant diﬀerence
in survival rates in pMP, pSS, pN0, and pN1 and among
Stage II, IIIA, and IIIB. Though there were limitations of
our study which was retrospectively conducted in a single
institute, and there was selection bias, our study would
suggest the beneﬁt of spleen preservation on postoperative
morbidity and long-term surgical outcomes. The overall
survival rate stratiﬁed by stage was analyzed in a prospective
randomized controlled trial [27], in which the 5-year overall
survival rates of patients with stage I, stage II, and stage III
were not signiﬁcantly diﬀerent between the 2 groups. Until
2005, our institute preferred to perform a total gastrectomy
with splenectomy in advanced proximal gastric cancer for
complete D2 lymphadenectomy. Recently we had a policy
of splenectomy for the patients with No. 10 enlargement
in the splenic hilum suggesting metastasis or tumor located
in greater curvature or encircling in upper third portion of
the stomach. A randomized controlled trail to evaluate total
gastrectomy with splenectomy for proximal advanced gastric
carcinoma with R0 resection (JCOG0110-MF) [28]h a s
already recruited 505 patients and resulted that splenectomy
was associated with higher morbidity and larger blood loss
and was safely performed by specialized surgeons with low
mortality. The precise impact of splenectomy on prognosis
remains uncertain and the impact on long-term survival
should be awaited.
In conclusion, although splenectomy for patients with
proximal advanced gastric cancer was not an important
risk factor for postoperative morbidity, splenectomy was not
eﬀective for patients with No. 10 metastasis in long-term
survival. Spleen-preserving total gastrectomy will be feasible
and be enough to accomplish radical surgery for locally
advanced proximal gastric cancer.
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